George is founder and Managing Director of 30 Ventures, a Madison-based early-stage venture capital firm focused on early-stage medical diagnostics, biotechnology tools, medical device, and industrial water and chemistry opportunities in the Midwest. George currently chairs the boards of directors for Chromatin, Inc. and Juventas Therapeutics, Inc., and is an Advisor to Ventures Investors LLC. George previously served as board chair of Zystor Therapeutics (acquired by BioMarin Pharmaceutical Inc. – NASDAQ: BMRN), Nerites Corporation (acquired by Kensey Nash, now DSM – Euronext: DSM), and Celleration, Inc. (acquired by Alliqua BioMedical, Inc. – NASDAQ: ALQA). George is a founding director of the Mid-America Healthcare Investors Network, an association of over forty regional venture capital firms active in early stage healthcare investing, and has served as an advisor to various incubators, accelerators, venture conferences, and to the Federal Reserve Bank of Chicago. He periodically guest-lectures at the University of Chicago Booth School of Business and the University of Wisconsin business school on the topics of entrepreneurship and venture capital. George previously served as CFO for Capital Resource Advisors, a financial firm in Chicago, and prior to that he spent 12 years in the industrial water and specialty chemicals industries at U.S. Filter, Betz Laboratories and Alar Engineering. George has a BS in Chemical Engineering from the University of Illinois and an MBA with high honors from University of Chicago Booth School of Business.
Hugo Braun has been an active venture capital investor in the Midwest and California since 1987 and is a cofounder and director of North Coast Technology Investors. Mr. Braun evaluates hundreds of investment opportunities per year, has acted as lead investor in both equity and subordinated debt investments, and has served on the boards of directors of public and private companies.
Prior to founding North Coast, Mr. Braun was a partner in Access Ventures, a Michigan based investment firm with over $30 million under management. In addition, he has co-managed BankAmerica Venture Capital’s $100 million venture portfolio. Investments included computer hardware and software, semiconductors, medical devices, telecommunications and retail. Mr. Braun was also a management consultant with Strategic Planning Associates, a spin-off of the Boston Consulting Group based in Washington, DC. While at SPA, he assisted Fortune 500 clients in the beverage, apparel, petroleum and chemical industries with corporate and financial strategies.
He received an M.S. in Management from the Sloan School of Management at MIT in 1985. He graduated magna cum laude with distinction from Yale University in 1980 with a B.A. in Economics.
Chad D. Costley, M.D.
Dr. Costley earned his M.D. degree from the University of Michigan where he also completed his undergraduate studies in English Literature. Following medical school, he remained at the University of Michigan to complete his residency training and is board-certified in Family Medicine. He has practiced medicine for over fifteen years in a variety of settings including teaching hospitals, urgent care centers, and outpatient clinics. While his background includes significant pediatric and obstetric experience, Dr. Costley now concentrates his practice on providing comprehensive care to teenage and adult patients. He has a particular interest in sports medicine and disease prevention.
In addition to his medical background, Dr. Costley holds a MBA degree from Emory University and serves on the board of directors of several technology start-up companies. Dr. Costley met his wife LeighAnn at the University of Michigan, and together they have two sons. He enjoys distance running, cooking, and spending time in the Smoky Mountains where enjoys fly-fishing.
Gary E. Costley, Ph.D.
Gary E. Costley, Ph.D., is co-founder and managing director of C&G Capital and Management, LLC, which provides capital and executive management support to health, nutritional, and medical product companies. Previously, he served as Chairman and Chief Executive Officer of International Multifoods Corporation, a manufacturer and marketer of branded consumer food and food service products.
Earlier in his career, Dr. Costley served in numerous executive management positions at Kellogg Company, including most recently as President of Kellogg North America. He currently also serves on the Board of Directors for Covance Inc., The Principal Financial Group, Tiffany & Co., and Prestige Brand Holdings, Inc.
Dave Peralta has served as the company’s Chief Executive Officer since 2013. He joined BlueWillow (then known as NanoBio Corporation) in 2006 and served as the company’s Chief Operating and Financial Officer through 2012. Dave was promoted to Chief Executive Officer in 2013 and has directed the company’s strategic shift towards use of its nanotechnology platform for the development of intranasal vaccines for respiratory and sexually transmitted diseases.
Prior to joining BlueWillow, Dave served as Chief Financial Officer for Arbortext, Inc., a venture-backed enterprise software company, up through the company’s acquisition in 2005. Before joining Arbortext, Dave served for six years as the Chief Financial Officer of Mechanical Dynamics, a publicly-held software company, where he directed all finance and investor relations activities during the company’s initial public offering and up through the sale of the company in 2002.
Dave earned a BBA, with distinction, from the University of Michigan Ross School of Business. He currently resides in Northville, Michigan, with his wife Rose and their four children.
David M. Stout
David M. Stout has served as a top-level pharmaceutical executive, both nationally and internationally, for the past 30 years. His most recent position was President of Pharmaceutical Operations for GlaxoSmithKline Pharmaceuticals. In this capacity, he led all global commercial activities, global manufacturing, and all vaccine-related activities for the company, including research and development. Additionally, Mr. Stout directed the corporate pandemic flu preparedness program – an international effort that supports governments, health authorities, and company employees around the world in responding to a global influenza pandemic.
Prior to his tenure at GSK, Mr. Stout served as President of SmithKline Beecham’s North American pharmaceutical business, launching two major products and two sales force expansions. His pharmaceutical career began at Warner-Lambert Pharmaceutical Company and continued at Schering-Plough Corporation, where he served in numerous positions, including President of Schering Laboratories.